MetaCap

Capricor Therapeutics (CAPR) vs Indaptus Therapeutics (INDP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 52.4% versus a gain of 32.0%. Over five years, CAPR leads with a +122.6% price change compared with -98.3% for INDP. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $433.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%INDP+52.43%
+543%+233%-78%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%INDP-98.22%
+1012%+430%-152%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus INDP key metrics
MetricCAPRINDP
Share price$7.59$2.82
Market cap$441.30M$433.16M
1-day change+0.80%-9.90%
YTD return-73.70%-3.09%
1-year return+32.00%+52.43%
5-year return+122.58%-98.26%
EPS (TTM)$-2.65$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-105.04M$-20.85M
52-week high$40.37$5.96
52-week low$2.96$0.92
Distance from 52-week high-81.20%-52.68%
Analyst consensusbuy—
Avg. price target upside+259.03%—
Average volume4.73M712.87K
Shares outstanding58.14M153.60M
Employees2315
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed CAPR by 20.4 percentage points over the past year.

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CAPR vs INDP FAQ

Which is bigger, Capricor Therapeutics or Indaptus Therapeutics?

Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $433.16M for Indaptus Therapeutics (INDP).

Which stock has performed better over the past year, CAPR or INDP?

INDP returned +52.43% over the past 12 months, compared with +32.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and Indaptus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons